Navigation Links
Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint

label, Phase II proof-of-concept, eight-patient study conducted at Virginia Commonwealth University, Oxycyte was administered to patients with severe traumatic brain injury and a Glasgow Coma Scale score of 3-9. The study protocol includes two groups. The first four study patients were stabilized with 50% oxygen for four hours before and 12 hours following Oxycyte administration. The remaining four study patients breathed 100% oxygen on the same schedule. Clinical data on brain oxygen and metabolite levels are compared in patients from both groups. The primary purpose of this study is to demonstrate Oxycyte's ability to increase brain oxygen tension and favorably affect other brain chemistries that impact clinical outcome in patients suffering severe head injury. Additionally, the study will further assess the safety of Oxycyte when given by intravenous infusion.

Due to a technical malfunction whereby a complete measurement of oxygen levels in the brain of one treated patient was not made, nine patients were treated during this study to meet the eight-patient enrollment goal. While survival was not a trial endpoint, seven patients in the trial survived their brain trauma. Neither of the two mortality cases was related to the safety of Oxycyte. One patient suffered massive injury and was not expected to survive. Another patient was withdrawn from the trial upon the voluntary decision to remove life-support.

About Synthetic Blood International

Synthetic Blood International is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a blood substitute, a liquid ventilation product and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for perfluorocarbons, and medical and industrial applications for biosensors. Each of the product candidates is designed with ad
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:10/2/2014)... 1, 2014 The global high content screening ... the ,Threat of Obsolescence, wherein technologies as well as ... and biotechnology companies as well as academic and government ... as a powerful research tool in drug discovery. The ... in the high content screening market. In high content ...
(Date:10/1/2014)... Oct. 1, 2014  Dyadic International, Inc. ("Dyadic") ... and proprietary technology used to develop and produce ... chemicals, biopharmaceuticals, and industrial enzymes industries, today announced ... Abengoa Bioenergy for commercial scale production of Abengoa,s ... ethanol, developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... 1, 2014 Trovagene, Inc., (NASDAQ:  TROV) ... that Eli Diamond , MD, Assistant Attending ... presented clinical data from an ongoing study demonstrating ... for the determination of oncogene mutational status in ... results were presented to both treating physicians and ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... The Leukemia & Lymphoma,Society has awarded a $550,000 grant ... Cancer Center at the University of Rochester Medical,Center. Millennium ... the first two years of the five-year program., ... support,Dr. Friedberg,s work on a new targeted treatment for ...
... Medivation, Inc.,(Nasdaq: MDVN ) today announced that ... on Monday, July 7, to discuss top-line results ... of,dimebon(TM) in Huntington,s disease., Teleconference/Webcast Details, ... July 7, at 5:00 p.m. Eastern,time by telephone, ...
Cached Medicine Technology:University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society 2Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntington's Disease 2
(Date:10/1/2014)... new research study published today in the Journal ... patients older than 50 years with moderate or severe ... , Researchers from the University of Melbourne randomly assigned ... pain to no acupuncture or sham or pretend laser ... with participants and acupuncturists blinded to laser and sham ...
(Date:10/1/2014)... Patients with increased inflammation, including those receiving ... risk of depression. For example, a 6-month treatment ... virus infection causes depression in approximately 30% of ... known as fish oil, have a long list ... heart disease and reducing triglyceride levels. These nutritional ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Familylifeinsurancequotes.org ... find life insurance for senior citizens. , Senior ... Agencies will now sell coverage to seniors who are ... can be purchased without taking a medical examination. , ... purchased online and senior clients can qualify. Having life ...
(Date:10/1/2014)... Bedros Keuilian is not only the ... boot camps, he’s also considered the leading expert on ... out business summits, a line of high-demand fitness marketing ... recent Spike TV reality show to his name. , ... time for personal trainers and fitness business owners to ...
(Date:10/1/2014)... Oregon (PRWEB) October 01, 2014 Phoseon ... solutions , continues to expand the business worldwide. This ... along with additional capacity for manufacturing efforts. The company ... the last five years and expects this growth to ... LED curing technology gains worldwide adoption. , “We ...
Breaking Medicine News(10 mins):Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... Finn, Jr., C.P.A. ("Finn") announced today that he has ... Brussels Branch. The statement is quoted in its entirety ... is a carbohydrate molecule which inhibits the activity of Galectin-3, ... of human cancers. Prospect reported that GCS-100 could induce ...
... studies show, , FRIDAY, June 5 (HealthDay News) -- One ... often not that interesting. But what if you could dance ... studies suggest that you just might be able to do ... Medicine meeting in Seattle, one study found that salsa dancing ...
... health centres and 680 pharmacies in the region are ready ... June 5 The Extremadura Regional Government of Spain and ... prescription system in 680 pharmacies in Extremadura, where health centres ... dispense prescription medications electronically. , , (Logo: ...
... who undergo myocardial infarction are experiencing onerous fatigue four months ... those who perceive the infarction as a sign of chronic ... and those who believe that the illness has a large ... thesis presented at the Sahlgrenska Academy, University of Gothenburg, Sweden. ...
... , MENTOR, Ohio, June 5 Join STERIS Isomedix Services ... critical to success in medical device sterilization ... 23, will provide attendees the opportunity to learn about sterilization ... , In addition to the TechTeam experts from STERIS Isomedix ...
... Ostomy Care Nurses Now Available Online , , ... and marketer of innovative medical technologies for community and ... (TM), an online, interactive community and resource. ... ostomy healthcare providers and will be unveiled at the ...
Cached Medicine News:Health News:Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Inc's. GCS-100 Molecule 2Health News:Finding Fitness on the Dance Floor 2Health News:Finding Fitness on the Dance Floor 3Health News:Spain's Regional Extremadura Government Launches Electronic Prescription System With IBM 2Health News:Fatigue common after myocardial infarction 2Health News:Medical Device Sterilization Seminar Offered by STERIS Isomedix Services 2Health News:Medical Device Sterilization Seminar Offered by STERIS Isomedix Services 3Health News:ConvaTec Launches New Programs to Support and Recognize WOC Nursing 2Health News:ConvaTec Launches New Programs to Support and Recognize WOC Nursing 3
... PACHETT 3 uses the exact enhanced corneal ... DGH pachymeters used exclusively by the OHTS ... into the software. The new backlit LCD ... average, standard deviation and IOP correction calculation ...
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
... E300 Corneal Topographer has applications ... clinical procedures including Radial Keratotomy, ... Contact Lens Fitting. Based on ... the E300 analyses an accurate ...
... first Open Bore MR ,Siemens has combined, for ... bore, a very short 125 cm magnet and ... very revolutionary: Open Bore MR. And MAGNETOM Espree, ... A unique Siemens technology, which means faster, more ...
Medicine Products: